Ivermectin and COVID | Is Ivermectin a Game Changer to Treat COVID? | COVID Medicine Update Today
In this video, I will be discussing the anti-parasitic drug, ivermectin, that some physicians are using to treat active COVID infections, and what some suggest is working on chronic COVID patients, also known as “long haulers.” Ivermectin referred to as “a wonder drug” before the COVID pandemic because of its safety and versatility, is now the center of controversy.
In April 2020, the FDA advised against using animal ivermectin to prevent people from self-medicating because of the potential for harmful effects. However, there are enough small studies and anecdotal evidence to consider ivermectin and conduct more clinical trials to make some conclusive statements.
Ivermectin is part of a class of drugs called “avermectins” discovered from the bacterium Streptomyces avermitilis in 1975 by researcher Dr. Satoshi Omura purified into ivermectin by Merck researcher, Dr. William Campbell.
Their efforts and discovery of ivermectin that saved millions of lives led to both of them receiving the 2015 Nobel Prize in Physiology or Medicine.
Ivermectin was first introduced in 1981 as a commercial product for animal health and was first used in humans in 1988 to treat onchocerciasis, also known as river blindness.
If we look at the mechanism of action, we know that ivermectin targets glutamate-gated chloride channels to paralyze and kill the worm's offspring. In COVID, it has been suggested that ivermectin works by inhibiting proteins involved in the shuttling of the viral component from the cytoplasm to the nucleus, thus reducing the replication of the virus and thereby the viral load.
While the use of ivermectin in parasitic infections is well documented, evidence and studies suggest that ivermectin possesses antiviral, anticancer, and immunomodulating properties.
A 280 patient retrospect study conducted at 4 hospitals in Broward County, Florida, a peer-reviewed publication, reported lower mortality in the ivermectin group, lower mortality among patients with severe pulmonary disease treated with ivermectin difference successful extubation rates.
Links to the studies I discussed in the video:
Dr. Omura's review: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3043740/
Dr. Rajter's peer-reviewed paper: https://journal.chestnet.org/article/S0012-3692(20)34898-4/fulltext
Bangladesh/ Dr. Mohiuddin preprint paper: https://www.researchsquare.com/article/rs-38896/v1
India pre-print: https://www.medrxiv.org/content/10.1101/2020.10.29.20222661v1
#covid19 #covid #ivermectin